Shikonin, a potent PKM2 inhibitor in cancer cells and macrophages 86, can effectively prevent the release of inflammasomes, and findings suggest that pharmacologic inhibition of PKM2 by shikonin selectively suppresses NLRP3 and AIM2 inflammasome activation and reduces sepsis by inhibiting PKM2-dependent glycolysis 84. The gene discussed is PKM; the disease is cancer.